A chikungunya fever vaccine utilizing an insect-specific virus platform

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

63 Scopus Citations
View graph of relations

Author(s)

  • Jesse H Erasmus
  • Albert J Auguste
  • Jason T Kaelber
  • Huanle Luo
  • Shannan L Rossi
  • Karla Fenton
  • Grace Leal
  • Wah Chiu
  • Tian Wang
  • Ilya Frolov
  • Farooq Nasar
  • Scott C Weaver

Detail(s)

Original languageEnglish
Pages (from-to)192-199
Journal / PublicationNature Medicine
Volume23
Issue number2
Online published19 Dec 2016
Publication statusPublished - Feb 2017
Externally publishedYes

Abstract

Traditionally, vaccine development involves tradeoffs between immunogenicity and safety. Live-attenuated vaccines typically offer rapid and durable immunity but have reduced safety when compared to inactivated vaccines. In contrast, the inability of inactivated vaccines to replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and boosters. To overcome these tradeoffs, we developed the insect-specific alphavirus, Eilat virus (EILV), as a vaccine platform. To address the chikungunya fever (CHIKF) pandemic, we used an EILV cDNA clone to design a chimeric virus containing the chikungunya virus (CHIKV) structural proteins. The recombinant EILV/CHIKV was structurally identical at 10 Å to wild-type CHIKV, as determined by single-particle cryo-electron microscopy, and it mimicked the early stages of CHIKV replication in vertebrate cells from attachment and entry to viral RNA delivery. Yet the recombinant virus remained completely defective for productive replication, providing a high degree of safety. A single dose of EILV/CHIKV produced in mosquito cells elicited rapid (within 4 d) and long-lasting (>290 d) neutralizing antibodies that provided complete protection in two different mouse models. In nonhuman primates, EILV/CHIKV elicited rapid and robust immunity that protected against viremia and telemetrically monitored fever. Our EILV platform represents the first structurally native application of an insect-specific virus in preclinical vaccine development and highlights the potential application of such viruses in vaccinology.

Citation Format(s)

A chikungunya fever vaccine utilizing an insect-specific virus platform. / Erasmus, Jesse H; Auguste, Albert J; Kaelber, Jason T; Luo, Huanle; Rossi, Shannan L; Fenton, Karla; Leal, Grace; Kim, Dal Y.; Chiu, Wah; Wang, Tian; Frolov, Ilya; Nasar, Farooq; Weaver, Scott C.

In: Nature Medicine, Vol. 23, No. 2, 02.2017, p. 192-199.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review